Clinical Care Options Hepatitis - HCV via MedWorm.com MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Clinical Care Options Hepatitis - HCV' source. Sun, 28 Feb 2010 14:27:20 +0100 Updates in HCV Treatment http://www.medworm.com/index.php?rid=3137090&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference+Coverage%2FAASLD+2009%2FTracks%2FHCV+Treatment%2FHCV_Treatment.aspx Learning Module - In this Expert Analysis, Michael P. Manns, MD; David R. Nelson, MD; and Tram T. Tran, MD, provide an in-depth review of the most important new data presented at the 2009 AASLD meeting on the management of patients with chronic HCV infection. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3137090 Wed, 30 Dec 2009 12:00:00 +0100 3137090 Smoother Waters Ahead? New Directions in the Management of HCV http://www.medworm.com/index.php?rid=3137091&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment+Updates%2FHCV+New+Directions%2FInteractive+Virtual+Presentation%2FIVP.aspx Resource - This program provides insights into the magnitude of the HCV epidemic and current challenges when treating patients with chronic hepatitis C, helping participants navigate data from recent and ongoing clinical trials of STAT-C agents and understand their potential impact on HCV management including the prospects for reduced durations and increased efficacy of treatment in both treatment-naive and treatment-experienced patient populations. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3137091 Fri, 18 Dec 2009 12:00:00 +0100 3137091 Lessons Learned: Best Practices in the Management of Patients Who Previously Failed HCV Treatment http://www.medworm.com/index.php?rid=3137092&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment+Updates%2FHCV+Lessons%2FInteractive+Virtual+Presentation%2FHCV_Lessons.aspx Resource - Brian L. Pearlman, MD, FACP, reviews key considerations and supporting clinical data pertinent to the management of HCV nonresponders using currently available regimens. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3137092 Fri, 18 Dec 2009 09:16:11 +0100 3137092 Slideset: Lessons Learned: Best Practices in the Management of Patients Who Previously Failed HCV Treatment http://www.medworm.com/index.php?rid=3313079&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHCV%2520Lessons%2FInteractive%2520Virtual%2520Presentation%2FLessons_Learned_Slides.aspx CCO Slideset - Brian L. Pearlman, MD, FACP, discusses management strategies for patients who have failed HCV treatment. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3313079 Mon, 14 Dec 2009 11:23:33 +0100 3313079 Lessons Learned: Best Practices in the Management of Patients Who Previously Failed HCV Treatment http://www.medworm.com/index.php?rid=3137093&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment+Updates%2FHCV+Lessons%2FInteractive+Virtual+Presentation%2FLessons_Learned_Slides.aspx CCO Slideset - Brian L. Pearlman, MD, FACP, discusses management strategies for patients who have failed HCV treatment. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3137093 Mon, 14 Dec 2009 11:23:33 +0100 3137093 Highlights From AASLD 2009 http://www.medworm.com/index.php?rid=3137094&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference+Coverage%2FAASLD+2009%2FCCO+Slideset%2FAASLD_2009_Highlights.aspx CCO Slideset - Review the most clinically relevant new data from the 2009 AASLD conference on HCV, HBV, and complications of advanced liver disease. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3137094 Tue, 17 Nov 2009 00:00:00 +0100 3137094 Addition of Thymosin alpha-1 to Peginterferon alfa-2a Plus Ribavirin in Previous Nonresponder, Primarily Genotype 1 HCV Population Does Not Increase SVR Rate by Intent-to-Treat Analysis http://www.medworm.com/index.php?rid=3137095&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference+Coverage%2FAASLD+2009%2FTracks%2FHCV+Treatment%2FCapsules%2F1564.aspx Capsule Summary - Previous nonresponder HCV patients with undetectable HCV RNA at Week 24, and who complete 48-week treatment, may achieve higher SVR rates with addition of thymosin alpha-1 to peginterferon alfa-2a plus ribavirin vs addition of placebo. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3137095 Thu, 05 Nov 2009 17:02:55 +0100 3137095 PARADIGM: High-Dose Ribavirin Plus Peginterferon alfa-2a not Associated With Improved SVR Rate in HCV/HIV-Coinfected Patients http://www.medworm.com/index.php?rid=3137096&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference+Coverage%2FAASLD+2009%2FTracks%2FHCV+Treatment%2FCapsules%2F1561.aspx Capsule Summary - Higher SVR rates observed among HCV/HIV-coinfected patients achieving RVR or cEVR, regardless of the ribavirin dose. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3137096 Thu, 05 Nov 2009 13:06:11 +0100 3137096 Robust Antiviral Activity of NS5B Polymerase Inhibitor MK-3281 in Patients Infected With Genotype 1b HCV During 7-Day Monotherapy http://www.medworm.com/index.php?rid=3137099&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference+Coverage%2FAASLD+2009%2FTracks%2FHCV+Treatment%2FCapsules%2F1568.aspx Capsule Summary - In blinded safety analysis, headache, migraine, dizziness, tiredness, decreased libido, and abdominal pain were the most frequently reported adverse events. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3137099 Thu, 05 Nov 2009 12:00:00 +0100 3137099 Among HCV-Infected Patients With Poor Prognostic Indicators, Telaprevir-Based Therapy Significantly Improved Virologic Response vs Standard of Care http://www.medworm.com/index.php?rid=3137097&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference+Coverage%2FAASLD+2009%2FTracks%2FHCV+Treatment%2FCapsules%2F1565.aspx Capsule Summary - Logistic regression analyses identified white race as prognostic for SVR (P = .02) and male sex as predictive of RVR (P = .04) among patients treated with the telaprevir-based regimen. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3137097 Thu, 05 Nov 2009 12:00:00 +0100 3137097 Robust Antiviral Activity of NS5B Polymerase Inhibitor MK-3281 in Patients Infected With Genotype 1b HCV During 7-Day Monotherapy http://www.medworm.com/index.php?rid=2965057&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202009%2FTracks%2FHCV%2520Treatment%2FCapsules%2F1568.aspx Capsule Summary - In blinded safety analysis, headache, migraine, dizziness, tiredness, decreased libido, and abdominal pain were the most frequently reported adverse events. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2965057 Thu, 05 Nov 2009 12:00:00 +0100 2965057 Among HCV-Infected Patients With Poor Prognostic Indicators, Telaprevir-Based Therapy Significantly Improved Virologic Response vs Standard of Care http://www.medworm.com/index.php?rid=2965056&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202009%2FTracks%2FHCV%2520Treatment%2FCapsules%2F1565.aspx Capsule Summary - Logistic regression analyses identified white race as prognostic for SVR (P = .02) and male sex as predictive of RVR (P = .04) among patients treated with the telaprevir-based regimen. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2965056 Thu, 05 Nov 2009 12:00:00 +0100 2965056 Patient and Graft Survival Lower Among HCV/HIV-Coinfected vs HCV-Monoinfected Liver Transplantation Recipients, but Incidence of Severe Posttransplantation Recurrence of HCV Disease Similar http://www.medworm.com/index.php?rid=3137103&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference+Coverage%2FAASLD+2009%2FTracks%2FManagement+of+HBV%2FCapsules%2F195.aspx Capsule Summary - According to a multivariate analysis, independent predictors of graft loss in HIV/HCV-coinfected patients include low BMI, dual organ (kidney and liver) transplantation, HCV-positive donor, and treatment for acute rejection. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3137103 Wed, 04 Nov 2009 12:00:00 +0100 3137103 INFORM-1: First Interferon-Free Combination Therapy With Direct-Acting Antiviral Agents RG7128 and RG7227 Safe and Effective in Chronic Genotype 1 HCV Patients http://www.medworm.com/index.php?rid=3137102&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference+Coverage%2FAASLD+2009%2FTracks%2FHCV+Treatment%2FCapsules%2F193.aspx Capsule Summary - RG7128/RG7227 combination oral regimen well tolerated during 14 days of therapy in genotype 1 HCV treatment-naive and treatment-experienced patients. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3137102 Wed, 04 Nov 2009 12:00:00 +0100 3137102 Preliminary Data Suggest Virologic Benefit of Nitazoxanide Plus Peginterferon alfa-2a/Ribavirin in Cirrhotic Patients Infected With Genotype 1 HCV Who Failed Previous Peginterferon/Ribavirin Therapy http://www.medworm.com/index.php?rid=3137101&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference+Coverage%2FAASLD+2009%2FTracks%2FHCV+Treatment%2FCapsules%2F1580.aspx Capsule Summary - No serious adverse events occurred during combination therapy with nitazoxanide plus peginterferon alfa-2a/ribavirin in this pilot study. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3137101 Wed, 04 Nov 2009 12:00:00 +0100 3137101 Final Results of Study C208: High Rates of SVR Achieved With Telaprevir/Peginterferon/Ribavirin Combination Therapy in Treatment-Naive Patients With Chronic Genotype 1 HCV Infection http://www.medworm.com/index.php?rid=3137100&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference+Coverage%2FAASLD+2009%2FTracks%2FHCV+Treatment%2FCapsules%2F194.aspx Capsule Summary - Sustained virologic response rates were similar for patients receiving telaprevir dosed every 8 hours vs every 12 hours. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3137100 Wed, 04 Nov 2009 12:00:00 +0100 3137100 Patient and Graft Survival Lower Among HCV/HIV-Coinfected vs HCV-Monoinfected Liver Transplantation Recipients, but Incidence of Severe Posttransplantation Recurrence of HCV Disease Similar http://www.medworm.com/index.php?rid=2961021&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202009%2FTracks%2FManagement%2520of%2520HBV%2FCapsules%2F195.aspx Capsule Summary - According to a multivariate analysis, independent predictors of graft loss in HIV/HCV-coinfected patients include low BMI, dual organ (kidney and liver) transplantation, HCV-positive donor, and treatment for acute rejection. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2961021 Wed, 04 Nov 2009 12:00:00 +0100 2961021 INFORM-1: First Interferon-Free Combination Therapy With Direct-Acting Antiviral Agents RG7128 and RG7227 Safe and Effective in Chronic Genotype 1 HCV Patients http://www.medworm.com/index.php?rid=2961020&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202009%2FTracks%2FHCV%2520Treatment%2FCapsules%2F193.aspx Capsule Summary - RG7128/RG7227 combination oral regimen well tolerated during 14 days of therapy in genotype 1 HCV treatment-naive and treatment-experienced patients. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2961020 Wed, 04 Nov 2009 12:00:00 +0100 2961020 Preliminary Data Suggest Virologic Benefit of Nitazoxanide Plus Peginterferon alfa-2a/Ribavirin in Cirrhotic Patients Infected With Genotype 1 HCV Who Failed Previous Peginterferon/Ribavirin Therapy http://www.medworm.com/index.php?rid=2961019&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202009%2FTracks%2FHCV%2520Treatment%2FCapsules%2F1580.aspx Capsule Summary - No serious adverse events occurred during combination therapy with nitazoxanide plus peginterferon alfa-2a/ribavirin in this pilot study. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2961019 Wed, 04 Nov 2009 12:00:00 +0100 2961019 Final Results of Study C208: High Rates of SVR Achieved With Telaprevir/Peginterferon/Ribavirin Combination Therapy in Treatment-Naive Patients With Chronic Genotype 1 HCV Infection http://www.medworm.com/index.php?rid=2961018&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202009%2FTracks%2FHCV%2520Treatment%2FCapsules%2F194.aspx Capsule Summary - Sustained virologic response rates were similar for patients receiving telaprevir dosed every 8 hours vs every 12 hours. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2961018 Wed, 04 Nov 2009 12:00:00 +0100 2961018 NEXT-1: Adding Narlaprevir to Standard Peginterferon alfa-2b/Ribavirin Regimen Produces Rapid Virologic Response in Treatment-Naive Patients With Chronic Genotype 1 Hepatitis C Infection http://www.medworm.com/index.php?rid=3137104&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference+Coverage%2FAASLD+2009%2FTracks%2FHCV+Treatment%2FCapsules%2FLB4.aspx Capsule Summary - The adverse event profile of narlaprevir-based therapy was similar to peginterferon alfa-2b/ribavirin, but with a higher incidence of anemia and dizziness. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3137104 Tue, 03 Nov 2009 19:39:45 +0100 3137104 SILEN-C1: High Rate of Virologic Response at Weeks 4 and 12 With Addition of BI 201335 to Standard of Care for First-line Treatment of Genotype 1 HCV Infection http://www.medworm.com/index.php?rid=3137106&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference+Coverage%2FAASLD+2009%2FTracks%2FHCV+Treatment%2FCapsules%2FLB3.aspx Capsule Summary - The incidence of pruritus, jaundice, and rash was higher among patients treated with BI 201335–based combination therapy compared with patients receiving peginterferon alfa-2a/ribavirin alone. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3137106 Tue, 03 Nov 2009 12:00:00 +0100 3137106 HCC Risk Remains High Following at Least 12 Months of Antiviral Therapy in Cirrhotic Patients With Chronic Hepatitis B http://www.medworm.com/index.php?rid=3137105&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference+Coverage%2FAASLD+2009%2FTracks%2FManagement+of+HBV%2FCapsules%2F137.aspx Capsule Summary - A multivariate analysis identified cirrhosis, older age, and male sex as independent predictors of hepatocellular carcinoma incidence in patients receiving at least 12 months of oral antiviral therapy, most of which was lamivudine based. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3137105 Tue, 03 Nov 2009 12:00:00 +0100 3137105 SILEN-C1: High Rate of Virologic Response at Weeks 4 and 12 With Addition of BI 201335 to Standard of Care for First-line Treatment of Genotype 1 HCV Infection http://www.medworm.com/index.php?rid=2956493&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202009%2FTracks%2FHCV%2520Treatment%2FCapsules%2FLB3.aspx Capsule Summary - The incidence of pruritus, jaundice, and rash was higher among patients treated with BI 201335–based combination therapy compared with patients receiving peginterferon alfa-2a/ribavirin alone. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2956493 Tue, 03 Nov 2009 12:00:00 +0100 2956493 Smoother Waters Ahead? New Directions in the Management of HCV http://www.medworm.com/index.php?rid=3137107&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment+Updates%2FHCV+New+Directions%2FSlideset%2FSlides.aspx CCO Slideset - This downloadable slideset created by expert faculty provides insights into the magnitude of the HCV epidemic and current challenges when treating patients with HCV infection. The slides also review data from recent and ongoing clinical trials of STAT-C agents in late clinical development and their potential impact on HCV management. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3137107 Tue, 03 Nov 2009 00:00:00 +0100 3137107 PROVE 3: SVR Improved With Telaprevir Combined With Peginterferon alfa-2a/Ribavirin Therapy in Genotype 1 HCV Patients Failing Previous Regimen; 1-Year Durability Demonstrated http://www.medworm.com/index.php?rid=3137108&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference+Coverage%2FAASLD+2009%2FTracks%2FHCV+Treatment%2FCapsules%2F66.aspx Capsule Summary - Response rates were significantly higher with telaprevir/peginterferon/ribavirin regimens vs peginterferon/ribavirin alone in previous nonresponders or relapsers to peginterferon/ribavirin treatment. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3137108 Mon, 02 Nov 2009 16:52:50 +0100 3137108 SPRINT-1: Up to 55% of Genotype 1 HCV Patients With Null Response After 4 Weeks of Peginterferon/Ribavirin Lead-in Achieved SVR With Triple-Therapy Regimen Containing Boceprevir http://www.medworm.com/index.php?rid=3137109&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference+Coverage%2FAASLD+2009%2FTracks%2FHCV+Treatment%2FCapsules%2F62.aspx Capsule Summary - Sustained virologic response rates were higher among Week 4 null responders who received subsequent 44 weeks of triple therapy with boceprevir relative to those who received only 24 weeks of triple therapy. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3137109 Mon, 02 Nov 2009 16:13:46 +0100 3137109 A2ALL Interim Analysis: Virologic Response 12 Weeks After Liver Transplantation Feasible With Pretransplantation Peginterferon alfa-2b/Ribavirin Therapy http://www.medworm.com/index.php?rid=3137110&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference+Coverage%2FAASLD+2009%2FTracks%2FManagement+of+HBV%2FCapsules%2F1.aspx Capsule Summary - Although pre–liver transplantation peginterferon alfa-2b/ribavirin effectively prevented HCV recurrence posttransplantation in a subset of patients, serious adverse event rates were higher among patients who received peginterferon/ribavirin therapy prior to liver transplantation relative to patients who did not receive pretransplantation therapy. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3137110 Mon, 02 Nov 2009 09:50:02 +0100 3137110 Genetic Marker Strongly Associated With SVR to Peginterferon/Ribavirin in Patients With Genotype 1 HCV http://www.medworm.com/index.php?rid=2932591&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FGe_Nature_2009%2FSlideset.aspx CCO Slideset - In this genomewide association study, a genetic polymorphism near IL28B, which encodes for interferon lambda-3, was found to strongly correlate with response to peginterferon/ribavirin in individuals infected with genotype 1 HCV. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2932591 Tue, 27 Oct 2009 12:40:13 +0100 2932591 IDEAL: Peginterferon alfa-2a and Peginterferon alfa-2b Regimens Demonstrate Comparable SVR Efficacy http://www.medworm.com/index.php?rid=2932593&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FMcHutchison_NEJM_2009_CS%2FSlideset.aspx CCO Slideset - In this large, randomized trial, SVR rates were similar among patients receiving low-dose peginterferon alfa-2b, standard-dose peginterferon alfa-2b, and standard-dose peginterferon alfa-2a, although differences in end-of-treatment response rates, relapse rates, and adverse events were noted. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2932593 Tue, 27 Oct 2009 00:00:00 +0100 2932593 Weight-Related Factors Associated With Risk for Liver Disease Progression According to Analysis of HALT-C Data http://www.medworm.com/index.php?rid=2932592&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FEverhart_Gastroenterol_2009%2FSlideset.aspx CCO Slideset - In this analysis of the HALT-C study, insulin resistance, histologic features of fatty liver disease, and weight changes were found to be associated with increased rates of liver disease progression in patients with chronic hepatitis C. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2932592 Tue, 27 Oct 2009 00:00:00 +0100 2932592 Higher Total Cholesterol and Lower Oxidative Stress Biomarker Predict Rapid Virologic Response to Peginterferon/Ribavirin in HCV-Infected Patients http://www.medworm.com/index.php?rid=2917973&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FAngelico_APT_2009%2FSlideset.aspx CCO Slideset - In a prospective study, younger age, non–genotype 1 HCV infection, higher baseline total cholesterol, and lower baseline 8-iso-prostaglandin F-2-alpha independently predicted rapid virologic response. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2917973 Wed, 21 Oct 2009 00:00:00 +0100 2917973 Standard-Duration HCV Treatment Superior to Individualized-Duration HCV Treatment Based on Time to HCV RNA Negativity by bDNA in Patients With Genotype 1 HCV http://www.medworm.com/index.php?rid=2917972&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FBerg-Hepatology-2009%2FSlideset.aspx CCO Slideset - In this prospective, randomized trial, the standard duration of 48 weeks with peginterferon/ribavirin was found to be superior to individualized treatment durations according to on-treatment response using a branched DNA assay for genotype 1 HCV patients; use of highly sensitive transcription-mediated amplification assay and consideration of baseline HCV RNA could result in higher response rates with individualized therapy. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2917972 Wed, 21 Oct 2009 00:00:00 +0100 2917972 Journal Options Slideset http://www.medworm.com/index.php?rid=2914061&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FAngelico_APT_2009%2FSlides.aspx CCO Slideset - In a prospective study, younger age, non–genotype 1 HCV infection, higher baseline total cholesterol, and lower baseline 8-iso-prostaglandin F-2-alpha independently predicted rapid virologic response. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2914061 Wed, 21 Oct 2009 00:00:00 +0100 2914061 Standard-Duration HCV Treatment Superior to Individualized-Duration HCV Treatment Based on Time to HCV RNA Negativity by bDNA in Patients With Genotype 1 HCV http://www.medworm.com/index.php?rid=2914060&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FBerg-Hepatology-2009%2FSlides.aspx CCO Slideset - In this prospective, randomized trial, the standard duration of 48 weeks with peginterferon/ribavirin was found to be superior to individualized treatment durations according to on-treatment response using a branched DNA assay for genotype 1 HCV patients; use of highly sensitive transcription-mediated amplification assay and consideration of baseline HCV RNA could result in higher response rates with individualized therapy. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2914060 Wed, 21 Oct 2009 00:00:00 +0100 2914060 Higher Total Cholesterol and Lower Oxidative Stress Biomarker Predict Rapid Virologic Response to Peginterferon/Ribavirin in HCV-Infected Patients http://www.medworm.com/index.php?rid=2917975&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FAngelico_APT_2009%2FCapsule.aspx Capsule Summary - In a prospective study, younger age, non–genotype 1 HCV infection, higher baseline total cholesterol, and lower baseline 8-iso-prostaglandin F-2-alpha independently predicted rapid virologic response. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2917975 Tue, 20 Oct 2009 00:00:00 +0100 2917975 Genetic Marker Strongly Associated With SVR to Peginterferon/Ribavirin in Patients With Genotype 1 HCV http://www.medworm.com/index.php?rid=2917974&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FGe_Nature_2009%2FCapsule.aspx Capsule Summary - In this genomewide association study, a genetic polymorphism near IL28B, which encodes for interferon lambda-3, was found to strongly correlate with response to peginterferon/ribavirin in individuals infected with genotype 1 HCV. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2917974 Tue, 20 Oct 2009 00:00:00 +0100 2917974 Standard-Duration HCV Treatment Superior to Individualized-Duration HCV Treatment Based on Time to HCV RNA Negativity by bDNA in Patients With Genotype 1 HCV http://www.medworm.com/index.php?rid=2896489&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FBerg-Hepatology-2009%2FCapsule.aspx Capsule Summary - In this prospective, randomized trial, the standard duration of 48 weeks with peginterferon/ribavirin was found to be superior to individualized treatment durations according to on-treatment response using a branched DNA assay for genotype 1 HCV patients; use of highly sensitive transcription-mediated amplification assay and consideration of baseline HCV RNA could result in higher response rates with individualized therapy. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2896489 Thu, 15 Oct 2009 00:00:00 +0100 2896489 HCV Treatment Candidacy in an HCV/HIV-Coinfected Patient Receiving HIV Therapy http://www.medworm.com/index.php?rid=2900521&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FManagement%2520Series%2F2009%2520AASLD%2520HCV%2520Guidelines%2FInteractive%2520Case%2520Challenges%2FCase_5.aspx Case Challenge - Norbert Bräu, MD, reviews the management of HCV in a patient coinfected with HIV. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2900521 Mon, 12 Oct 2009 16:53:43 +0100 2900521 HCV Treatment Candidacy in a HCV/HIV-Coinfected Patient Receiving HIV Therapy http://www.medworm.com/index.php?rid=2884352&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FManagement%2520Series%2F2009%2520AASLD%2520HCV%2520Guidelines%2FInteractive%2520Case%2520Challenges%2FCase_5.aspx Case Challenge - Norbert Bräu, MD, reviews the management of HCV in a patient coinfected with HIV. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2884352 Mon, 12 Oct 2009 16:53:43 +0100 2884352 IDEAL: Peginterferon alfa-2a and Peginterferon alfa-2b Regimens Demonstrate Comparable SVR Efficacy http://www.medworm.com/index.php?rid=2884353&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FMcHutchison_NEJM_2009_CS%2FCapsule.aspx Capsule Summary - In this large, randomized trial, SVR rates were similar among patients receiving low-dose peginterferon alfa-2b, standard-dose peginterferon alfa-2b, and standard-dose peginterferon alfa-2a, although differences in end-of-treatment response rates, relapse rates, and adverse events were noted. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2884353 Mon, 12 Oct 2009 09:14:26 +0100 2884353 Management and Treatment of Special Populations of HCV-Infected Patients http://www.medworm.com/index.php?rid=2867194&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FManagement%2520Series%2F2009%2520AASLD%2520HCV%2520Guidelines%2FInteractive%2520Virtual%2520Presentations%2FSpecial_Populations_Slides.aspx CCO Slideset - In this downloadable slideset, Ira M. Jacobson, MD, reviews the AASLD guideline recommendations for the treatment of special populations of HCV-infected persons. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2867194 Tue, 06 Oct 2009 09:08:10 +0100 2867194 Initial HCV Therapy in a Patient With Mild Depression http://www.medworm.com/index.php?rid=2867195&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FManagement%2520Series%2F2009%2520AASLD%2520HCV%2520Guidelines%2FInteractive%2520Case%2520Challenges%2FCase_1.aspx Case Challenge - Join K. Rajender Reddy, MD, in choosing the optimal treatment strategies for a patient with chronic HCV infection and a history of depression. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2867195 Tue, 06 Oct 2009 00:00:00 +0100 2867195 Weight-Related Factors Associated With Risk for Liver Disease Progression According to Analysis of HALT-C Data http://www.medworm.com/index.php?rid=2853614&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FEverhart_Gastroenterol_2009%2FCapsule.aspx Capsule Summary - In this analysis of the HALT-C study, insulin resistance, histologic features of fatty liver disease, and weight changes were found to be associated with increased rates of liver disease progression in patients with chronic hepatitis C. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2853614 Wed, 30 Sep 2009 00:00:00 +0100 2853614 Initial HCV Management, Treatment and Monitoring http://www.medworm.com/index.php?rid=2787344&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FManagement%2520Series%2F2009%2520AASLD%2520HCV%2520Guidelines%2FInteractive%2520Virtual%2520Presentations%2FInitial_Treatment.aspx CCO Virtual Presentation - John McHutchison, MD, FRACP, provides an overview of the AASLD 2009 guideline update on the initial management, treatment, and monitoring of patients with hepatitis C. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2787344 Fri, 11 Sep 2009 12:32:55 +0100 2787344 Management of a Genotype 1 HCV Patient in a Methadone Maintenance Program http://www.medworm.com/index.php?rid=2798398&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FManagement%2520Series%2F2009%2520AASLD%2520HCV%2520Guidelines%2FInteractive%2520Case%2520Challenges%2FCase_2.aspx Case Challenge - David R. Nelson, MD, discusses management strategies and AASLD recommendations involved in managing a treatment-naive genotype 1 HCV–infected patient who is participating in a methadone maintenance program (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2798398 Fri, 11 Sep 2009 00:00:00 +0100 2798398 Initial HCV Management, Treatment and Monitoring http://www.medworm.com/index.php?rid=2787349&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FManagement%2520Series%2F2009%2520AASLD%2520HCV%2520Guidelines%2FInteractive%2520Virtual%2520Presentations%2FInitial_Treatment_Slides.aspx CCO Slideset - In this downloadable slideset, John G. McHutchison, MD, FRACP, provides an update on the initial management, treatment, and monitoring of patients with hepatitis C. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2787349 Fri, 11 Sep 2009 00:00:00 +0100 2787349 Management of an HCV-Infected Compensated Cirrhotic Patient With Moderate Alcohol Use http://www.medworm.com/index.php?rid=2787348&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FManagement%2520Series%2F2009%2520AASLD%2520HCV%2520Guidelines%2FInteractive%2520Case%2520Challenges%2FCase_4.aspx Case Challenge - Guy Neff, MD, MBA, discusses the challenging management decisions involved in treating an HCV-infected compensated cirrhotic patient with moderate alcohol use. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2787348 Fri, 11 Sep 2009 00:00:00 +0100 2787348 Management and Treatment of Special Populations of HCV-Infected Patients http://www.medworm.com/index.php?rid=2787347&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FManagement%2520Series%2F2009%2520AASLD%2520HCV%2520Guidelines%2FInteractive%2520Virtual%2520Presentations%2FSpecial_Populations.aspx CCO Virtual Presentation - Ira M. Jacobson, MD, reviews the AASLD guideline recommendations for the treatment of special populations of HCV-infected persons. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2787347 Fri, 11 Sep 2009 00:00:00 +0100 2787347 Management of an Genotype 1 HCV Patient in a Methadone Maintenance Program http://www.medworm.com/index.php?rid=2787346&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FManagement%2520Series%2F2009%2520AASLD%2520HCV%2520Guidelines%2FInteractive%2520Case%2520Challenges%2FCase_2.aspx Case Challenge - David R. Nelson, MD, discusses management strategies and AASLD recommendations involved in managing a treatment-naive genotype 1 HCV–infected patient who is participating in a methadone maintenance program (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2787346 Fri, 11 Sep 2009 00:00:00 +0100 2787346 Management of an HCV-Infected Black Woman With Delayed Diagnosis and Treatment http://www.medworm.com/index.php?rid=2787345&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FManagement%2520Series%2F2009%2520AASLD%2520HCV%2520Guidelines%2FInteractive%2520Case%2520Challenges%2FCase_3.aspx Case Challenge - Maribel Rodriguez-Torres, MD, CPI, discusses the management of an HCV-infected black woman with significant liver disease due to delayed diagnosis and treatment. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2787345 Fri, 11 Sep 2009 00:00:00 +0100 2787345 Hepatitis Annual Update 2009 http://www.medworm.com/index.php?rid=2680062&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FAnnual%2520Updates%2F2009%2520Annual%2520Update%2FCCO%2520Slideset%2F2009_Annual_Update_Slides.aspx CCO Slideset - Review the latest data on HBV and HCV management, as well as the diagnosis and management of decompensated cirrhosis. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2680062 Fri, 07 Aug 2009 00:00:00 +0100 2680062 Update on Investigational HCV Agents http://www.medworm.com/index.php?rid=2632198&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FAnnual%2520Updates%2F2009%2520Annual%2520Update%2FModules%2FPawlotsky.aspx Learning Module - Jean-Michel Pawlotsky, MD, PhD, discusses how insights into the virology of HCV have unraveled several targets for potential novel therapeutics. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2632198 Thu, 23 Jul 2009 12:00:00 +0100 2632198 Mechanisms of Response and Nonresponse to HCV Treatment http://www.medworm.com/index.php?rid=2607829&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FAnnual%2520Updates%2F2009%2520Annual%2520Update%2FModules%2FChung.aspx Learning Module - Raymond T. Chung, MD, reviews the mechanisms of response and nonresponse in HCV treatment, including fixed and modifiable factors. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2607829 Thu, 16 Jul 2009 08:59:20 +0100 2607829 Hepatitis C Testing and Counseling: the Gateway to Treatment http://www.medworm.com/index.php?rid=2586154&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FManagement%2520Series%2F2009%2520AASLD%2520HCV%2520Guidelines%2FInteractive%2520Virtual%2520Presentations%2FTesting.aspx CCO Virtual Presentation - David L. Thomas, MD, MPH, discusses how risk-based testing can help identify the large population of undiagnosed patients infected with hepatitis C. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2586154 Thu, 09 Jul 2009 10:16:51 +0100 2586154 Hepatitis C Testing and Counseling: the Gateway to Treatment http://www.medworm.com/index.php?rid=2586155&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FManagement%2520Series%2F2009%2520AASLD%2520HCV%2520Guidelines%2FInteractive%2520Virtual%2520Presentations%2FTesting_Slides.aspx CCO Slideset - In this downloadable slideset, David L. Thomas, MD, MPH, discusses the importance of hepatitis C virus testing, as it is the first step in the management and treatment of HCV infection. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2586155 Thu, 09 Jul 2009 00:00:00 +0100 2586155 Update on the Management of HCV and the Complications of Liver Disease http://www.medworm.com/index.php?rid=2479946&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FCopenhagen%25202009%2FTracks%2FHCV%2520Treatment%2FHCV.aspx Learning Module - Join Adrian M. Di Bisceglie, MD, FACP; Michael P. Manns, MD; and Stefan Zeuzem, MD, as they discuss the most clinically relevant new data presented at 2009 EASL regarding the treatment of HCV infection and the management of complications associated with advanced liver disease. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2479946 Tue, 16 Jun 2009 13:04:30 +0100 2479946 2009 HCV Advanced Practice Curriculum: Fibrosis and Disease Progression in HCV http://www.medworm.com/index.php?rid=2479947&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHCV%2520Curriculum%25202009%2FInteractive%2520Virtual%2520Presentations%2FAdvanced%2520Liver%2520Disease.aspx CCO Virtual Presentation - Raymond T. Chung, MD, reviews complications of advanced liver disease, how to assess the severity of liver disease, and how treatment may address these complications. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2479947 Fri, 12 Jun 2009 14:08:49 +0100 2479947 Fibrosis and Disease Progression in HCV http://www.medworm.com/index.php?rid=2479948&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHCV%2520Curriculum%25202009%2FInteractive%2520Virtual%2520Presentations%2FAdvanced_Liver_Disease_Slides.aspx CCO Slideset - In this downloadable slideset, Raymond T. Chung, MD, reviews the complications associated with advanced liver disease, how to assess the severity of liver disease, and how treatment may affect outcomes. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2479948 Fri, 12 Jun 2009 14:06:25 +0100 2479948 PROVE 1: Combination of Telaprevir With Peginterferon/Ribavirin Significantly Increases SVR in Treatment-Naive Patients With HCV Genotype 1 http://www.medworm.com/index.php?rid=2444252&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FMcHutchison-NEJM-2009%2FSlideset.aspx CCO Slideset - In a randomized, placebo-controlled trial, the coadministration of telaprevir with peginterferon/ribavirin therapy allowed for a reduced duration of therapy from 48 weeks to 24 weeks without compromising SVR rates. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2444252 Fri, 29 May 2009 00:00:00 +0100 2444252 PROVE 1: Combination of Telaprevir With Peginterferon/Ribavirin Significantly Increases SVR in Treatment-Naive Patients With HCV Genotype 1 http://www.medworm.com/index.php?rid=2444253&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FMcHutchison-NEJM-2009%2FCapsule.aspx Capsule Summary - In a randomized, placebo-controlled trial, the coadministration of telaprevir with peginterferon/ribavirin therapy allowed for a reduced duration of therapy from 48 weeks to 24 weeks without compromising SVR rates. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2444253 Thu, 28 May 2009 00:00:00 +0100 2444253 2009 HCV Advanced Practice Curriculum: Current Management of HCV Treatment-Experienced Patients http://www.medworm.com/index.php?rid=2419448&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHCV%2520Curriculum%25202009%2FInteractive%2520Virtual%2520Presentations%2FTreatment-Experienced.aspx CCO Virtual Presentation - Maria H. Sjogren, MD, MPH, FACP, discusses current management options for HCV-infected, treatment-experienced patients. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2419448 Fri, 15 May 2009 12:00:00 +0100 2419448 Current Management of HCV Treatment-Experienced Patients http://www.medworm.com/index.php?rid=2419449&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHCV%2520Curriculum%25202009%2FInteractive%2520Virtual%2520Presentations%2FTreatment%2520Experienced%2520Slides.aspx CCO Slideset - In this downloadable slideset, Maria H. Sjogren, MD, discusses the rationale for retreating HCV nonresponders and explores treatment options for this subset of patients. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2419449 Fri, 15 May 2009 00:00:00 +0100 2419449 HALT-C: Long-term Maintenance Peginterferon alfa-2a Not Associated With Reduced Disease Progression Rates in Prior Nonresponders With Advanced Chronic HCV Infection http://www.medworm.com/index.php?rid=2393048&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FDi%2520Bisceglie-NEJM-2008%2FSlideset.aspx CCO Slideset - In a randomized, prospective trial, maintenance therapy with low-dose peginterferon alfa-2a 90 µg/week did not decrease the rate of clinical or histologic disease progression, incidence of hepatocellular carcinoma, or adverse events vs untreated patients. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2393048 Wed, 06 May 2009 09:07:10 +0100 2393048 Analysis of HALT-C Data Reveals Trends in Hepatocellular Carcinoma Incidence and Risk Factors in the United States http://www.medworm.com/index.php?rid=2393051&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FLok_Gastroenterol_2009%2FSlideset.aspx CCO Slideset - Using the large, well-characterized HALT-C cohort, a predictive model for the risk of HCC was developed based on age, race, alkaline phosphatase levels, presence of esophageal varices, smoking status, and platelet count. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2393051 Wed, 06 May 2009 00:00:00 +0100 2393051 Nitazoxanide Improves Rates of Response to Peginterferon/Ribavirin in Treatment-Naive Patients With Genotype 4 HCV http://www.medworm.com/index.php?rid=2393050&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FRossignol-Gastroenterol-2008%2FSlideset.aspx CCO Slideset - In a randomized trial of genotype 4 HCV–infected patients, higher RVR and SVR rates were observed in patients receiving nitazoxanide in combination with peginterferon/ribavirin therapy vs standard of care alone. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2393050 Wed, 06 May 2009 00:00:00 +0100 2393050 Consensus Interferon/Ribavirin Beneficial for Specific Groups of Difficult-to-Treat Prior Peginterferon/Ribavirin Nonresponders http://www.medworm.com/index.php?rid=2393049&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FBacon-Hepatology-2009%2FSlideset.aspx CCO Slideset - In this randomized trial comparing 2 consensus interferon/ribavirin regimens, successful retreatment of peginterferon/ribavirin nonresponders was associated with better response to prior therapy and lower baseline fibrosis scores. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2393049 Wed, 06 May 2009 00:00:00 +0100 2393049 Consensus Interferon/Ribavirin Beneficial for Specific Groups of Difficult-to-Treat Prior Peginterferon/Ribavirin Nonresponders http://www.medworm.com/index.php?rid=2384234&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FBacon-Hepatology-2009%2FCapsule.aspx Capsule Summary - In this randomized trial comparing 2 consensus interferon/ribavirin regimens, successful retreatment of peginterferon/ribavirin nonresponders was associated with better response to prior therapy and lower baseline fibrosis scores. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2384234 Thu, 30 Apr 2009 10:11:38 +0100 2384234 HALT-C: Long-term Maintenance Peginterferon alfa-2a Not Associated With Reduced Disease Progression Rates in Prior Nonresponders With Advanced Chronic HCV Infection http://www.medworm.com/index.php?rid=2378215&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FDi%2520Bisceglie-NEJM-2008%2FCapsule.aspx Capsule Summary - In a randomized, prospective trial, maintenance therapy with low-dose peginterferon alfa-2a 90 µg/week did not decrease the rate of clinical or histologic disease progression, incidence of hepatocellular carcinoma, or adverse events vs untreated patients. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2378215 Mon, 27 Apr 2009 00:00:00 +0100 2378215 SUCCESS: 72-Week Duration of Peginterferon alfa-2b/Weight-Based Ribavirin Does Not Significantly Improve SVR Rates in Genotype 1 HCV Slow Responders vs 48 Weeks of Therapy http://www.medworm.com/index.php?rid=2518731&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FCopenhagen%25202009%2FTracks%2FHCV%2520Treatment%2FCapsules%2F141.aspx Capsule Summary - Higher discontinuation rates and no significant SVR rate benefit with 72 vs 48 week PegIFN alfa-2b/RBV therapy in genotype 1 HCV slow responders. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2518731 Sun, 26 Apr 2009 14:48:50 +0100 2518731 72-Week PegIFN alfa-2b/Weight-Based RBV Does Not Significantly Improve SVR rates in Genotype 1 HCV Slow Responders vs 48 Weeks of Therapy http://www.medworm.com/index.php?rid=2371285&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FCopenhagen%25202009%2FTracks%2FHCV%2520Treatment%2FCapsules%2F141.aspx Capsule Summary - Higher discontinuation rates and no significant SVR rate benefit with 72 vs 48 week PegIFN alfa-2b/RBV therapy in genotype 1 HCV slow responders. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2371285 Sun, 26 Apr 2009 14:48:50 +0100 2371285 Nonnucleoside HCV Polymerase Inhibitor VCH-916 Safe and Active in Treatment-Naive Patients Infected With Genotype 1 HCV http://www.medworm.com/index.php?rid=2518732&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FCopenhagen%25202009%2FTracks%2FHCV%2520Treatment%2FCapsules%2F92.aspx Capsule Summary - Three days of monotherapy with VCH-916 resulted in a mean maximal HCV RNA decrease of 1.5 log10 IU/mL in patients with genotype 1 HCV. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2518732 Sun, 26 Apr 2009 09:54:01 +0100 2518732 Nonnucleoside HCV Polymerase Inhibitor VCH-916 Safe and Effective in Treatment-Naive Patients Infected With Genotype 1 HCV http://www.medworm.com/index.php?rid=2371286&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FCopenhagen%25202009%2FTracks%2FHCV%2520Treatment%2FCapsules%2F92.aspx Capsule Summary - Three days of monotherapy with VCH-916 resulted in a mean maximal HCV RNA decrease of 1.5 log10 IU/mL in patients with genotype 1 HCV. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2371286 Sun, 26 Apr 2009 09:54:01 +0100 2371286 Rapid HCV RNA Decline in Treatment-Naive Genotype 1 Patients With ITMN-191 Combined With Peginterferon alfa-2a Plus Ribavirin http://www.medworm.com/index.php?rid=2366325&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FCopenhagen%25202009%2FTracks%2FHCV%2520Treatment%2FCapsules%2F85.aspx Capsule Summary - Patients receiving ITMN-191 combination therapy with peginterferon alfa-2a plus ribavirin experienced rapid HCV RNA decline with no virologic rebound. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2366325 Sat, 25 Apr 2009 09:44:58 +0100 2366325 Nitazoxanide Improves Rates of Response to Peginterferon/Ribavirin in Treatment-Naive Patients With Genotype 4 HCV http://www.medworm.com/index.php?rid=2366327&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FRossignol-Gastroenterol-2008%2FCapsule.aspx Capsule Summary - In a randomized trial of genotype 4 HCV–infected patients, higher RVR rates and SVR rates were observed in patients receiving nitazoxanide in combination with peginterferon/ribavirin therapy vs standard of care alone. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2366327 Fri, 24 Apr 2009 00:00:00 +0100 2366327 Analysis of HALT-C Data Reveals Trends in Hepatocellular Carcinoma Incidence and Risk Factors in the United States http://www.medworm.com/index.php?rid=2366328&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FLok_Gastroenterol_2009%2FCapsule.aspx Capsule Summary - Using the large, well-characterized HALT-C cohort, a predictive model for the risk of HCC was developed based on age, race, alkaline phosphatase levels, presence of esophageal varices, smoking status and platelet count. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2366328 Thu, 23 Apr 2009 14:37:39 +0100 2366328 Immediate Treatment of Acute HCV More Effective Than Delayed Treatment in Overall Population, Similar in Adherent Patients http://www.medworm.com/index.php?rid=2518733&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FCopenhagen%25202009%2FTracks%2FHCV%2520Treatment%2FCapsules%2F1047.aspx Capsule Summary - SVR rates in acute HCV patients were higher overall with immediate treatment vs delayed treatment but rates comparable when adherence maintained and follow-up completed. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2518733 Fri, 17 Apr 2009 00:00:00 +0100 2518733 Boceprevir Added to Standard of Care Results in High Response Rates in Treatment-Naive Patients With Genotype 1 HCV http://www.medworm.com/index.php?rid=2366330&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FCopenhagen%25202009%2FTracks%2FHCV%2520Treatment%2FCapsules%2F4.aspx Capsule Summary - In this phase II trial, boceprevir nearly doubled SVR rates when combined with the standard of care vs standard of care alone in treatment-naive, genotype 1 patients. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2366330 Fri, 17 Apr 2009 00:00:00 +0100 2366330 SCH 900518 Safe and Effective Therapy for Patients Infected With Genotype 1 HCV http://www.medworm.com/index.php?rid=2366329&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FCopenhagen%25202009%2FTracks%2FHCV%2520Treatment%2FCapsules%2F86.aspx Capsule Summary - Rapid and continued decreases in HCV RNA levels were observed in both treatment-naive and treatment-experienced patients receiving SCH 900518 ± ritonavir ± peginterferon alfa-2b. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2366329 Fri, 17 Apr 2009 00:00:00 +0100 2366329 2009 HCV Advanced Practice Curriculum: The Importance of Patient Quality of Life http://www.medworm.com/index.php?rid=2310352&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHCV%2520Curriculum%25202009%2FInteractive%2520Virtual%2520Presentations%2FQuality%2520of%2520Life.aspx CCO Virtual Presentation - Vinod Rustgi, MD, discusses how hepatitis C infection impacts quality of life and how quality of life can impact the outcome of hepatitis C therapy. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2310352 Tue, 07 Apr 2009 12:00:00 +0100 2310352 The Importance of Patient Quality of Life http://www.medworm.com/index.php?rid=2310355&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHCV%2520Curriculum%25202009%2FInteractive%2520Virtual%2520Presentations%2FQuality%2520of%2520Life%2520Slides.aspx CCO Slideset - In this downloadable slideset, Vinod Rustgi, MD, discusses how hepatitis C infection impacts quality of life and how quality of life can impact the outcome of hepatitis C therapy. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2310355 Tue, 07 Apr 2009 00:00:00 +0100 2310355 Managing the Difficult-to-Treat HCV Patient http://www.medworm.com/index.php?rid=2264448&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FManagement%2520Series%2FMaximizing%2520HCV%2520Response%2FVirtual%2520Presentations%2FReddy%2520Slides.aspx CCO Slideset - Download a slideset focused strategies for managing patients with previous nonresponse or relapse during HCV therapy. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2264448 Fri, 13 Mar 2009 00:00:00 +0100 2264448 Prevention and Management of Thrombocytopenia in Hepatitis C Patients http://www.medworm.com/index.php?rid=2181418&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FThrombocytopenia%2FInteractive%2520Virtual%2520Presentation%2FSlideset.aspx CCO Slideset - This downloadable PowerPoint slideset reviews the impact of thrombocytopenia on the care of patients with chronic hepatitis C. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2181418 Wed, 11 Feb 2009 00:00:00 +0100 2181418 Management of an HCV-Infected Patient Using Virologic Responses to Therapy http://www.medworm.com/index.php?rid=2171895&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHCV%2520Management%2520Tools%2FInteractive%2520Case%2520Challenges%2FDougherty.aspx Case Challenge - Karen Dougherty, MSN, APRN, BC, discusses how response to HCV therapy can be used to make management decisions during treatment. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2171895 Mon, 09 Feb 2009 00:00:00 +0100 2171895 Retreatment of a Patient With Chronic HCV Infection and Previous Treatment Failure http://www.medworm.com/index.php?rid=2171894&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHCV%2520Nonresponders%2FInteractive%2520Case%2520Challenges%2FHassanein.aspx Case Challenge - Tarek Hassanein, MD, reviews management strategies for optimizing future therapy success in a HCV-infected patient with previous partial treatment response on a standard interferon-based regimen. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2171894 Mon, 09 Feb 2009 00:00:00 +0100 2171894 Depression and Suicidal Risk Associated With HCV Treatment http://www.medworm.com/index.php?rid=2171893&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHCV%2520and%2520Depression%2FModules%2FRaison.aspx Learning Module - Charles L. Raison, MD, discusses the adverse effect of depression associated with HCV therapy and the impact of depression on successful HCV treatment. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2171893 Mon, 09 Feb 2009 00:00:00 +0100 2171893 Management of an HCV-Infected Male With Advanced Liver Disease http://www.medworm.com/index.php?rid=2171891&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FManagement%2520Series%2FMaximizing%2520HCV%2520Response%2FInteractive%2520Case%2520Challenges%2FEverson%2520Case.aspx Case Challenge - Gregory T. Everson, MD, FACP, discusses management strategies for a patient with advanced hepatitis C. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2171891 Mon, 09 Feb 2009 00:00:00 +0100 2171891 Prevention and Management of Thrombocytopenia in Hepatitis C Patients http://www.medworm.com/index.php?rid=2152411&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FThrombocytopenia%2FInteractive%2520Virtual%2520Presentation%2FPrevention%2520and%2520Management.aspx CCO Virtual Presentation - Watch and listen as Robert S. Brown, Jr., MD, MPH, discusses the impact of thrombocytopenia on management of hepatitis C patients. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2152411 Mon, 02 Feb 2009 00:00:00 +0100 2152411 24 Weeks of Peginterferon/Ribavirin Determined Inferior to 48 Weeks, Even With RVR, in Asian Patients With HCV Genotype 1 http://www.medworm.com/index.php?rid=2089274&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FYu-Hepatology-2008%2FCapsule.aspx Capsule Summary - In a prospective, randomized, open-label study, significantly higher SVR rates were achieved among genotype 1 patients who received 48 vs 24 weeks of treatment, with RVR being the highest predictor of SVR in both groups. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2089274 Thu, 08 Jan 2009 14:55:48 +0100 2089274 Journal Options Slideset http://www.medworm.com/index.php?rid=2089275&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FYu-Hepatology-2008%2FSlideset.aspx CCO Slideset - In a prospective, randomized, open-label study, significantly higher SVR rates were achieved among genotype 1 patients who received 48 vs 24 weeks of treatment, with RVR being the highest predictor of SVR in both groups. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2089275 Thu, 08 Jan 2009 00:00:00 +0100 2089275 Journal Options Slideset http://www.medworm.com/index.php?rid=2089276&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FLoustaud-Ratti-Hepatology-2008%2FSlideset.aspx CCO Slideset - This pharmacodynamic study is the first to demonstrate that very early ribavirin exposure is associated with sustained virologic response rates in patients with genotype 1 HCV. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2089276 Wed, 07 Jan 2009 00:00:00 +0100 2089276 Journal Options Slideset http://www.medworm.com/index.php?rid=2080619&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FKorba-AAC-2008%2FSlideset.aspx CCO Slideset - This in vitro study suggests that resistance to nitazoxanide and tizoxanide does not occur because of genetic mutations in HCV RNA but rather because of cellular adaptations by the host cell—a mechanism that leads to increased sensitivity to interferon. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2080619 Mon, 05 Jan 2009 00:00:00 +0100 2080619 Journal Options Slideset http://www.medworm.com/index.php?rid=2080618&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FMangia-Hepatology-2008-COM%2FSlideset.aspx CCO Slideset - In this prospective randomized study, tailoring treatment duration based on on-treatment response in genotype 1 HCV–infected patients resulted in similar SVR rates to standard treatment durations. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2080618 Mon, 05 Jan 2009 00:00:00 +0100 2080618 Journal Options Slideset http://www.medworm.com/index.php?rid=2080621&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FFried-Hepatology-2008%2FSlideset.aspx CCO Slideset - In this randomized pilot study, higher doses of peginterferon alfa-2a and ribavirin were associated with greater HCV RNA decreases at Week 24, ultimately leading to higher SVR rates and lower relapse rates. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2080621 Fri, 02 Jan 2009 00:00:00 +0100 2080621 Journal Options Slideset http://www.medworm.com/index.php?rid=2080620&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FFerenci-Gastroenterol-2008%2FSlideset.aspx CCO Slideset - Study suggests abbreviated duration of pegIFN/RBV therapy may be sufficient in genotype 1 or 4 HCV–infected patients who achieve rapid virologic response. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2080620 Fri, 02 Jan 2009 00:00:00 +0100 2080620 2008 Update on the Use of Approved HCV Agents http://www.medworm.com/index.php?rid=2072518&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202008%2FTracks%2FApproved%2520HCV%2520Agents%2FApproved%2520HCV%2520Agents.aspx Learning Module - Join Gregory T. Everson, MD, FACP; Carroll Leevy, MD; and K. Rajender Reddy, MD, as they review new data on the optimization of currently approved HCV agents for the treatment of chronic HCV infection presented at the 2008 AASLD Meeting. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2072518 Fri, 02 Jan 2009 00:00:00 +0100 2072518 Higher Doses of Peginterferon Alfa-2a and Ribavirin Improve Outcomes in HCV-Infected Patients With Difficult-to-Treat Characteristics http://www.medworm.com/index.php?rid=2059471&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FFried-Hepatology-2008%2FCapsule.aspx Capsule Summary - In this randomized pilot study, higher doses of peginterferon alfa-2a and ribavirin were associated with greater HCV RNA decreases at Week 24, ultimately leading to higher SVR rates and lower relapse rates. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2059471 Mon, 22 Dec 2008 00:00:00 +0100 2059471 HCV Expert Recap of AASLD 2008 http://www.medworm.com/index.php?rid=2059472&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202008%2FVirtual%2520Presentation%2520Programs%2FHCV%2FHCV%2520ER.aspx CCO Expert Recap - Fred Poordad, MD, discusses results from key studies on the treatment of HCV infection presented at the 2008 Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco, California. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2059472 Fri, 19 Dec 2008 00:00:00 +0100 2059472 Individualized Peginterferon/Ribavirin Duration Based on On-Treatment Virologic Response Yields Sustained Virologic Response Rates Similar to Those of Standard Treatment in Genotype 1HCV http://www.medworm.com/index.php?rid=2055480&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FMangia-Hepatology-2008-COM%2FCapsule.aspx Capsule Summary - In this prospective randomized study, tailoring treatment duration based on on-treatment response in genotype 1 HCV–infected patients resulted in similar SVR rates to standard treatment durations. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2055480 Thu, 18 Dec 2008 09:01:14 +0100 2055480 Mechanism of Resistance to Anti-HCV Agents Nitazoxanide and Tizoxanide Complementary to Interferon Mechanism of Action http://www.medworm.com/index.php?rid=2038975&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FKorba-AAC-2008%2FCapsule.aspx Capsule Summary - Mechanism of Resistance to Anti-HCV Agents Nitazoxanide and Tizoxanide Complementary to Interferon Mechanism of Action (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2038975 Tue, 16 Dec 2008 00:00:00 +0100 2038975 Ribavirin Exposure on the First Day of Peginterferon/Ribavirin Dosing Correlates With Sustained Virologic Response in Patients With HCV Genotype 1 http://www.medworm.com/index.php?rid=2038976&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FLoustaud-Ratti-Hepatology-2008%2FCapsule.aspx Capsule Summary - This pharmacodynamic study is the first to demonstrate that very early ribavirin exposure is associated with sustained virologic response rates in patients with HCV genotype 1 . (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2038976 Mon, 15 Dec 2008 00:00:00 +0100 2038976 Thrombocytopenia in Hepatitis C: Impact on Patient Management http://www.medworm.com/index.php?rid=2032149&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FThrombocytopenia%2FModule%2FThrombocytopenia%2520in%2520Hepatitis%2520C.aspx Learning Module - Maribel Rodriguez-Torres, MD, discusses the etiology of thrombocytopenia, its impact on hepatitis C management, and emerging treatment strategies. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2032149 Thu, 11 Dec 2008 00:00:00 +0100 2032149 Reducing Nitazoxanide Pretreatment to 4 Weeks Does Not Compromise Antiviral Effect of Subsequent Nitazoxanide and Peginterferon alfa-2a Combination Therapy in Treatment-Naive HCV Patients http://www.medworm.com/index.php?rid=2025738&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicalcareoptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202008%2FTracks%2FInvestigational%2520HBV%2520and%2520HCV%2520Agents%2FCapsules%2F87.aspx Capsule Summary - SVR rates with 4-week nitazoxanide lead-in followed by 36 weeks of nitazoxanide plus peginterferon similar to that of patients treated with nitazoxanide plus peginterferon and ribavirin after a 12-week lead-in period of nitazoxanide monotherapy (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2025738 Fri, 21 Nov 2008 08:59:06 +0100 2025738 HCV Expert Recap of AASLD 2008 http://www.medworm.com/index.php?rid=2010373&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202008%2FVirtual%2520Presentation%2520Programs%2FHCV%2FHCV%2520Slides.aspx CCO Slideset - This downloadable slideset reviews the most clinically relevant new data on hepatitis C presented at the 2008 American Association for the Study of Liver Diseases Meeting. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2010373 Wed, 19 Nov 2008 11:34:43 +0100 2010373 Induction Therapy With High-Dose Peginterferon alfa-2b Does Not Improve SVR Rates in Treatment-Naive Patients With Genotype 1 HCV Infection http://www.medworm.com/index.php?rid=2010374&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202008%2FTracks%2FApproved%2520HCV%2520Agents%2FCapsules%2F208.aspx Capsule Summary - Induction therapy was associated with a nonsignificant trend toward higher response rates in heavier patients. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2010374 Fri, 07 Nov 2008 13:47:56 +0100 2010374 Adding Metformin to Standard Peginterferon alfa-2a/Ribavirin Regimen Improves Insulin Sensitivity in Patients With HCV Infection http://www.medworm.com/index.php?rid=2010375&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202008%2FTracks%2FApproved%2520HCV%2520Agents%2FCapsules%2FLB6.aspx Capsule Summary - Female genotype 1 HCV patients with insulin resistance experience higher SVR rates when metformin added to standard peginterferon alfa-2a/ribavirin regimen (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2010375 Fri, 07 Nov 2008 13:26:50 +0100 2010375 12-Week Telaprevir Induction With 24-Week Peginterferon alfa-2a/Ribavirin Therapy Achieves Higher SVR Rates Than 48-Week Standard of Care in Treatment-Naive Genotype 1 HCV Patients http://www.medworm.com/index.php?rid=2010378&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202008%2FTracks%2FInvestigational%2520HBV%2520and%2520HCV%2520Agents%2FCapsules%2F243.aspx Capsule Summary - Addition of ribavirin to 12-week telaprevir and peginterferon alfa-2a therapy associated with higher SVR rates (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2010378 Fri, 07 Nov 2008 12:00:00 +0100 2010378 Significantly Greater SVR Rates With Telaprevir-Based Therapy Than Standard of Care Retreatment in Previous Unsuccessfully Treated Genotype 1 HCV-Infected Patients http://www.medworm.com/index.php?rid=2010377&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202008%2FTracks%2FInvestigational%2520HBV%2520and%2520HCV%2520Agents%2FCapsules%2F269.aspx Capsule Summary - Inclusion of ribavirin to telaprevir and peginterferon alfa-2a treatment for 24 weeks in patients who previously failed HCV therapy associated with higher SVR rates (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2010377 Fri, 07 Nov 2008 12:00:00 +0100 2010377 Meta-analysis of 12 Randomized Controlled Trials Confirms Benefit of Extended Genotype 1 HCV Peginterferon alfa/ribavirin Treatment to 72 Weeks for Slow Responders http://www.medworm.com/index.php?rid=2010376&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202008%2FTracks%2FApproved%2520HCV%2520Agents%2FCapsules%2F213.aspx Capsule Summary - 16 weeks of peginterferon alfa/ribavirin HCV treatment noninferior to 24 weeks in HCV genotype 2/3 patients with rapid virologic response (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2010376 Fri, 07 Nov 2008 12:00:00 +0100 2010376 R7128 With Peginterferon alfa-2a and Ribavirin Produces High RVR Rates in Treatment-Naive Patients With Chronic Genotype 1 HCV Infection http://www.medworm.com/index.php?rid=2010379&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202008%2FTracks%2FInvestigational%2520HBV%2520and%2520HCV%2520Agents%2FCapsules%2F1899.aspx Capsule Summary - R7128 given twice daily with peginterferon alfa-2a/ribavirin produces high rates of RVR in treatment-naive patients infected with genotype 1 HCV (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2010379 Thu, 06 Nov 2008 16:38:53 +0100 2010379 Comparable Rates of HCV RNA Suppression With Telaprevir 2 or 3 Times Daily Plus Peginterferon/Ribavirin in Treatment-Naive Patients With Genotype 1 HCV Infection http://www.medworm.com/index.php?rid=2010380&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202008%2FTracks%2FInvestigational%2520HBV%2520and%2520HCV%2520Agents%2FCapsules%2F1854.aspx Capsule Summary - No significant differences observed in Day 14 virologic response with telaprevir in combination with ribavirin and either peginterferon alfa-2a or peginterferon alfa-2b (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2010380 Thu, 06 Nov 2008 15:34:01 +0100 2010380 R7128 Plus Peginterferon Alfa-2a/Ribavirin Produces High RVR Rates in Previous Nonresponders Infected With Genotype 2 or 3 HCV http://www.medworm.com/index.php?rid=2010381&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202008%2FTracks%2FInvestigational%2520HBV%2520and%2520HCV%2520Agents%2FCapsules%2FLB10.aspx Capsule Summary - Significant antiviral effect of R7128 plus peginterferon alfa-2a/ribavirin seen in patients infected with HCV genotype 2 or 3 who failed previous treatment with peginterferon alfa-2a/ribavirin (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2010381 Thu, 06 Nov 2008 12:09:38 +0100 2010381 Nonnucleoside HCV Polymerase Inhibitor PF-00868554 Safe and Effective in Treatment-Naive Patients Infected With Genotype 1 HCV http://www.medworm.com/index.php?rid=2010384&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202008%2FTracks%2FInvestigational%2520HBV%2520and%2520HCV%2520Agents%2FCapsules%2FLB11.aspx Capsule Summary - PF-00868554 monotherapy leads to potent dose-dependent suppression of HCV RNA in treatment-naive patients infected with genotype 1 HCV (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2010384 Thu, 06 Nov 2008 12:00:00 +0100 2010384 Weight-Based Taribavirin Demonstrates Similar Efficacy, Less Anemia vs Ribavirin When Both Combined With Peginterferon alfa-2b http://www.medworm.com/index.php?rid=2010383&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202008%2FTracks%2FInvestigational%2520HBV%2520and%2520HCV%2520Agents%2FCapsules%2F272.aspx Capsule Summary - Incidence of mild to moderate diarrhea higher with taribavirin vs ribavirin but less anemia and comparable efficacy observed vs ribavirin (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2010383 Thu, 06 Nov 2008 12:00:00 +0100 2010383 Rapid Decline in HCV RNA Followed by Viral Breakthrough With BI201335 Monotherapy in Treatment-Naive, Genotype 1 HCV-Infected Patients http://www.medworm.com/index.php?rid=2010382&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202008%2FTracks%2FInvestigational%2520HBV%2520and%2520HCV%2520Agents%2FCapsules%2F1849.aspx Capsule Summary - Higher doses of BI201335 were associated with an increase in the rate of unconjugated hyperbilirubinemia during 14 days of BI201335 monotherapy (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2010382 Thu, 06 Nov 2008 12:00:00 +0100 2010382 Low SVR Rates for Treatment-Naive Genotype 1 HCV-Infected Patients With Advanced Fibrosis or Cirrhosis at Baseline: Results of Canadian POWeR Study http://www.medworm.com/index.php?rid=2010385&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202008%2FTracks%2FApproved%2520HCV%2520Agents%2FCapsules%2F1216.aspx Capsule Summary - Low SVR in patients with advanced liver disease at baseline in Canadian POWeR study (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2010385 Thu, 06 Nov 2008 10:20:48 +0100 2010385 4-Week Nonresponse to Peginterferon alfa/Ribavirin Predicts HCV-Infected Patient’s Failure to Achieve SVR http://www.medworm.com/index.php?rid=2010386&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202008%2FTracks%2FApproved%2520HCV%2520Agents%2FCapsules%2F1247.aspx Capsule Summary - Failure to achieve at least a 1 log10 decrease in HCV RNA at treatment Week 4 was associated with a low rate of SVR and a high rate of nonresponse (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2010386 Thu, 06 Nov 2008 09:58:13 +0100 2010386 Insulin Resistance Associated With Lower Probability of SVR in HCV-Infected Patients Treated With Peginterferon alfa/Ribavirin http://www.medworm.com/index.php?rid=2010387&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202008%2FTracks%2FApproved%2520HCV%2520Agents%2FCapsules%2F1270.aspx Capsule Summary - Insulin resistance in nondiabetic, treatment-naive patients with chronic HCV treated with peginterferon alfa/ribavirin predicts low probability of SVR (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2010387 Thu, 06 Nov 2008 09:48:43 +0100 2010387 Use of Growth Factors to Prevent Peginterferon alfa-2b/Ribavirin Dose Reductions Does Not Improve Overall SVR Rates in Small Genotype 1 HCV Study http://www.medworm.com/index.php?rid=2010388&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202008%2FTracks%2FApproved%2520HCV%2520Agents%2FCapsules%2F209.aspx Capsule Summary - Small study finds SVR rate for patients receiving growth factors for treatment-related cytopenias numerically higher than those who did not (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2010388 Wed, 05 Nov 2008 13:20:53 +0100 2010388 Lower Relapse Rate With 72 vs 48 Weeks of Peginterferon alfa-2b Plus Ribavirin for Chronic Genotype 1 HCV-Infected Patients With Late Viral Response http://www.medworm.com/index.php?rid=2010389&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202008%2FTracks%2FApproved%2520HCV%2520Agents%2FCapsules%2F1224.aspx Capsule Summary - A significant association was observed between achieving undetectable levels of HCV RNA at earlier time points and lower rates of relapse among patients with late virologic response who were treated for 72 weeks (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2010389 Wed, 05 Nov 2008 12:49:18 +0100 2010389 Adding Boceprevir to Standard Peginterferon/Ribavirin Regimen Boosts SVR Rates in Treatment-Naive Patients Chronically Infected With Genotype 1 HCV http://www.medworm.com/index.php?rid=2010391&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202008%2FTracks%2FInvestigational%2520HBV%2520and%2520HCV%2520Agents%2FCapsules%2FLB16.aspx Capsule Summary - Inclusion of a 4-week peginterferon/ribavirin lead-in period prior to the addition of boceprevir to the regimen may reduce incidence of virologic breakthrough (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2010391 Wed, 05 Nov 2008 12:00:00 +0100 2010391 Higher SVR Rates for Patients With Advanced Fibrosis/Cirrhosis Infected With Genotype 2 vs Genotype 3 HCV Following Treatment With Peginterferon alfa-2a and Ribavirin http://www.medworm.com/index.php?rid=2010390&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202008%2FTracks%2FApproved%2520HCV%2520Agents%2FCapsules%2F1239.aspx Capsule Summary - Rapid virologic response was found to be associated with higher rates of SVR for both genotype 2 and 3 HCV (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=2010390 Wed, 05 Nov 2008 12:00:00 +0100 2010390 Expert Analysis: Focus on Investigational HCV Agents http://www.medworm.com/index.php?rid=1917482&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FMilan%25202008%2FTracks%2FInvestigational%2520HCV%2FInvest%2520HCV.aspx Nezam H. Afdhal, MD, FRCPI; Ira M. Jacobson, MD; and Stefan Zeuzem, MD, discuss the latest data on novel agents for the treatment of chronic hepatitis C. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=1917482 Thu, 30 Oct 2008 09:13:20 +0100 1917482 Treatment of a Genotype 1a Patient Not Achieving Full Virologic Suppression With Peginterferon/Ribavirin at 24 Weeks http://www.medworm.com/index.php?rid=1900128&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FTreatment-Experienced%2520HCV%2FInteractive%2520Case%2520Challenges%2FCase%25201.aspx Maria Sjogren, MD, discusses the treatment management options for patients not achieving HCV RNA suppression after 24 weeks of peginterferon alfa-2b/ribavirin. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=1900128 Fri, 24 Oct 2008 09:46:24 +0100 1900128 Management of HCV Nonresponders http://www.medworm.com/index.php?rid=1814764&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FTreatment-Experienced%2520HCV%2FVirtual%2520Presentations%2FVirtual%2520Presentation%25201.aspx Join Ira M. Jacobson, MD, as he discusses treatment strategies for the optimal management of patients with chronic hepatitis C with previous nonresponse to antiviral therapy. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=1814764 Tue, 23 Sep 2008 09:43:51 +0100 1814764 Clinical Data and Best Practices for Managing Depression in HCV-Infected Patients Treated With Peginterferon and Ribavirin http://www.medworm.com/index.php?rid=1805568&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHCV%2520and%2520Depression%25202008%2FModules%2FSpecial%2520Topic%2520Report.aspx Martin Schaefer, MD, highlights management strategies for patients with hepatitis C virus infection and depression, highlighting new studies from the past year (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=1805568 Fri, 19 Sep 2008 09:19:32 +0100 1805568 Retreatment in a Patient Failing Previous Therapy http://www.medworm.com/index.php?rid=1733119&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FManagement%2520Series%2FMaximizing%2520HCV%2520Response%2FInteractive%2520Case%2520Challenges%2FCroghan%2520Case.aspx Anne Croghan, MN, ARNP, discusses treatment options and predictors of response for patients relapsing on previous peginterferon/ribavirin therapy. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=1733119 Wed, 27 Aug 2008 08:23:07 +0100 1733119 Strategies for Management of Hepatitis C Treatment Failure http://www.medworm.com/index.php?rid=1699776&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FAnnual%2520Updates%2F2008%2520Annual%2520Update%2FModules%2FLindsay.aspx Karen L. Lindsay, MD, MMM, reviews the latest data on the management of patients who were nonresponders or relapsers during HCV therapy. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=1699776 Wed, 13 Aug 2008 09:48:10 +0100 1699776 New Data on Currently Available HCV Therapies and Their Impact on Initial Treatment Strategies http://www.medworm.com/index.php?rid=1654835&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FAnnual%2520Updates%2F2008%2520Annual%2520Update%2FModules%2FSulkowski.aspx Mark S. Sulkowski, MD, reviews principles and strategies for hepatitis C treatment using currently available therapeutic agents. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=1654835 Sat, 26 Jul 2008 08:02:56 +0100 1654835 Expert Recap: Focus on Investigational HCV Agents http://www.medworm.com/index.php?rid=1541516&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FMilan%25202008%2FVirtual%2520Presentation%2520Programs%2FInvestigational%2520HCV%2520ER%2FInvest%2520HCV.aspx Ira M. Jacobson, MD, discusses the latest data on novel agents for the treatment of chronic hepatitis C. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=1541516 Wed, 25 Jun 2008 20:54:49 +0100 1541516 Expert Analysis: Update on Investigational Agents in HCV: 2007 http://www.medworm.com/index.php?rid=1232873&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBoston%25202007%2FTracks%2FInvestigational%2520HCV%2FInvestigational%2520HCV.aspx Nezam H. Afdhal, MD, FRCPI, Ira M. Jacobson, MD, and David R. Nelson, MD review data from the meeting in Boston. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=1232873 Fri, 15 Feb 2008 08:20:32 +0100 1232873 Exper Recap: Update on Investigational Agents in HCV: 2007 http://www.medworm.com/index.php?rid=1214833&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBoston%25202007%2FVirtual%2520Presentation%2520Programs%2FInvestigational%2520HCV%2520ER.aspx Watch and listen as Ira M. Jacobson, MD, reviews key data on investigational HCV agents presented at the 2007 Boston liver disease meeting. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=1214833 Thu, 07 Feb 2008 20:26:51 +0100 1214833 Robust Response to Peginterferon alfa-2b Plus Ribavirin Among HCV-Infected IV Drug Users on Opioid Maintenance in Large German Cohort http://www.medworm.com/index.php?rid=1151945&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBoston%25202007%2FTracks%2FSpecial%2520Issues%2FCapsules%2F253.aspx HCV-infected IV drug users undergoing opioid maintenance therapy achieve response rates similar to patients not undergoing opioid therapy when adjusted for age, HCV genotype, and baseline HCV RNA level. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=1151945 Tue, 15 Jan 2008 21:33:53 +0100 1151945 Favorable HCV, HBV Outcomes in HCV/HBV-Coinfected Patients Treated With Peginterferon alfa-2a Plus Ribavirin http://www.medworm.com/index.php?rid=1133564&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBoston%25202007%2FTracks%2FSpecial%2520Issues%2FCapsules%2F233.aspx Peginterferon alfa-2a plus ribavirin therapy resulted in similar rates of HCV clearance when compared with HCV-monoinfected patients and led to HBsAg clearance in a significant proportion of patients at end-of-treatment follow-up (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=1133564 Tue, 08 Jan 2008 00:15:37 +0100 1133564 Biweekly Administration of Controlled-Release Recombinant Interferon alfa-2b Appears to Be Effective and Well Tolerated in Patients With HCV Genotype 1 http://www.medworm.com/index.php?rid=1133563&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBoston%25202007%2FTracks%2FInvestigational%2520HCV%2FCapsules%2FLB10.aspx Phase IIa study of controlled-release recombinant interferon alfa-2b demonstrates potent antiviral activity and is well tolerated among HCV genotype 1-infected, treatment-naive patients (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=1133563 Tue, 08 Jan 2008 00:15:37 +0100 1133563